Skip to main content

Table 5 Changes of gray matter volume from baseline to month 6 in the treatment group

From: Safety and efficacy outcomes after intranasal administration of neural stem cells in cerebral palsy: a randomized phase 1/2 controlled trial

 

Baseline

6 M

P value

Total volume

614,239.25 ± 39,964.24

623,498.50 ± 40,216.82

0.438

49 (SOG.L)

4924.49 ± 685.36

5164.16 ± 729.92

0.035*

52 (MOG.R)

8141.31 ± 1263.95

8737.89 ± 1148.10

0.019*

53 (IOG.L)

4474.26 ± 485.94

4860.14 ± 544.49

0.042*

54 (IOG.R)

4239.01 ± 797.49

4680.28 ± 814.30

0.023*

56 (FFG.R)

11,843.16 ± 1078.77

12,450.73 ± 960.36

0.008**

60 (SPG.R)

5877.22 ± 960.71

6482.12 ± 926.72

0.005**

62 (IPL.R)

5238.69 ± 587.67

5713.49 ± 566.96

0.007**

66 (ANG.R)

6505.39 ± 727.61

7008.39 ± 871.93

0.043*

87 (TPOmid.L)

2390.20 ± 654.50

2586.36 ± 506.35

0.031*

  1. 6 M: 6 months after treatment; SOG.L: Superior occipital gyrus; MOG.R: Middle occipital gyrus; IOG.L: Inferior occipital gyrus; IOG.R: Inferior occipital gyrus; FFG.R: Fusiform gyrus; SPG.R: Superior parietal gyrus; IPL.R: Inferior parietal, but supramarginal and angular gyri; ANG.R: Angular gyrus; TPOmid.L: Temporal pole: middle temporal gyrus
  2. *P < 0.05; **P < 0.01
Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512